Ester Caballero
Acute Care · New Brunswick, NJNPI 1548744642
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,574 of the $7,187 with a category attached, or 63.6%. 24 manufacturers reported payments, led by Abbott at 54.5% of the total. 2025 is the largest year on record at $3,573, more than ten times the $79 reported in 2021. Among acute care clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $66.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Cvrx, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$399
- United Therapeutics Corporation$196
- Takeda Pharmaceuticals U.S.A., Inc.$175
- Actelion Pharmaceuticals US, Inc.$165
- plus $1K from 18 others
What the payments were for
- Travel & lodging$2,61236%
- Food & beverage$4,57464%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 40 | $3,914 |
| Cvrx, Inc. | 12 | $1,283 |
| E.r. Squibb & Sons, L.L.C. | 7 | $399 |
| United Therapeutics Corporation | 5 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $175 |
| Actelion Pharmaceuticals US, Inc. | 6 | $165 |
| Daiichi Sankyo Inc. | 2 | $142 |
| Abiomed | 2 | $133 |
| Kestra Medical Technology Services, Inc. | 2 | $111 |
| Merck | 6 | $106 |
| Mallinckrodt Hospital Products Inc. | 1 | $105 |
| Irhythm Technologies, Inc. | 2 | $94 |
| Atricure, Inc. | 2 | $65 |
| Pfizer | 4 | $62 |
| Bridgebio Pharma, Inc. | 2 | $34 |
| Bayer | 2 | $32 |
| One Lambda, Inc. | 2 | $30 |
| Endotronix, Inc. | 1 | $27 |
| Impulse Dynamics (USA) Inc. | 1 | $27 |
| Novartis | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Boehringer Ingelheim | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$3,234
- Barostim Neo System$1,069
- CAMZYOS$351
- INJECTAFER$125
- LIVTENCITY$114
- TERLIVAZ$105
How this compares
$7,187 in reported general payments places this provider in the 95th percentile of 656 acute care providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 20 | $23,721 |
| JardianceEmpagliflozin | 20 | $21,837 |
| FarxigaDapagliflozin Propanediol | 17 | $8,924 |
| Sildenafil Citrate | 15 | $1,978 |
| Rosuvastatin Calcium | 21 | $496 |
| Metoprolol Succinate | 23 | $312 |
| Potassium Chloride | 17 | $203 |
| Hydralazine Hcl | 15 | $173 |
| Atorvastatin Calcium | 12 | $114 |
| Carvedilol | 18 | $73 |
| Spironolactone | 11 | $40 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $20 | $23,72120 claims |
| Boehringer IngelheimJardiance | $17 | $21,83720 claims |
| AstraZenecaFarxiga | $14 | $8,92417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 656 acute care providers in New Jersey.
Other acute care in New Brunswick
- Sally CascioNew Brunswick$12K
- Vashtie RamjattanNew Brunswick$6K
- Amita AvadhaniNew Brunswick$4K
- Jodelle GoldNew Brunswick$3K
- Gabriella MagarelliHackensack$44K
- Per RosenkvistLivingston$29K
- Matthew OstroffPaterson$27K
- Ellen McCueNeptune$26K
- Suzanne ShuggLivingston$25K
- Maria Tedi CoronelHackensack$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.